310 related articles for article (PubMed ID: 31062825)
1. Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force.
Cummings J; Blennow K; Johnson K; Keeley M; Bateman RJ; Molinuevo JL; Touchon J; Aisen P; Vellas B
J Prev Alzheimers Dis; 2019; 6(3):157-163. PubMed ID: 31062825
[TBL] [Abstract][Full Text] [Related]
2. Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report.
Bateman RJ; Blennow K; Doody R; Hendrix S; Lovestone S; Salloway S; Schindler R; Weiner M; Zetterberg H; Aisen P; Vellas B
J Prev Alzheimers Dis; 2019; 6(3):169-173. PubMed ID: 31062827
[TBL] [Abstract][Full Text] [Related]
3. Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force.
Gauthier S; Alam J; Fillit H; Iwatsubo T; Liu-Seifert H; Sabbagh M; Salloway S; Sampaio C; Sims JR; Sperling B; Sperling R; Welsh-Bohmer KA; Touchon J; Vellas B; Aisen P
J Prev Alzheimers Dis; 2019; 6(3):164-168. PubMed ID: 31062826
[TBL] [Abstract][Full Text] [Related]
4. Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU/US CTAD Task Force.
Aisen PS; Bateman RJ; Carrillo M; Doody R; Johnson K; Sims JR; Sperling R; Vellas B
J Prev Alzheimers Dis; 2021; 8(3):306-312. PubMed ID: 34101788
[TBL] [Abstract][Full Text] [Related]
5. Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer's Disease Task Force.
Cummings J; Fox N; Vellas B; Aisen P; Shan G
J Prev Alzheimers Dis; 2018; 5(2):103-109. PubMed ID: 29616703
[TBL] [Abstract][Full Text] [Related]
6. Anti-amyloid-β Antibodies and Anti-tau Therapies for Alzheimer's Disease: Recent Advances and Perspectives.
Suzuki N; Hatta T; Ito M; Kusakabe KI
Chem Pharm Bull (Tokyo); 2024; 72(7):602-609. PubMed ID: 38945936
[TBL] [Abstract][Full Text] [Related]
7. Current thinking on the mechanistic basis of Alzheimer's and implications for drug development.
Ising C; Stanley M; Holtzman DM
Clin Pharmacol Ther; 2015 Nov; 98(5):469-71. PubMed ID: 26250900
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacology of novel anti-Alzheimer disease modifying medications.
Caraci F; Bosco P; Leggio GM; Malaguarnera M; Drago F; Bucolo C; Salomone S
Curr Top Med Chem; 2013; 13(15):1853-63. PubMed ID: 23931438
[TBL] [Abstract][Full Text] [Related]
9. Progression of Alzheimer's disease, tau propagation, and its modifiable risk factors.
Takeda S
Neurosci Res; 2019 Apr; 141():36-42. PubMed ID: 30120962
[TBL] [Abstract][Full Text] [Related]
10. Alzheimer's disease (AD) therapeutics - 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality.
Mullane K; Williams M
Biochem Pharmacol; 2018 Dec; 158():359-375. PubMed ID: 30273553
[TBL] [Abstract][Full Text] [Related]
11. Key Peptides and Proteins in Alzheimer's Disease.
Penke B; Bogár F; Paragi G; Gera J; Fülöp L
Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for Alzheimer's disease.
Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
[TBL] [Abstract][Full Text] [Related]
13. The past, present, and future of disease-modifying therapies for Alzheimer's disease.
Suzuki K; Iwata A; Iwatsubo T
Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(10):757-771. PubMed ID: 29225305
[TBL] [Abstract][Full Text] [Related]
14. Tau Biology and Tau-Directed Therapies for Alzheimer's Disease.
Bakota L; Brandt R
Drugs; 2016 Mar; 76(3):301-13. PubMed ID: 26729186
[TBL] [Abstract][Full Text] [Related]
15. Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies.
Golde TE
J Neurochem; 2016 Oct; 139 Suppl 2(Suppl 2):224-236. PubMed ID: 27145445
[TBL] [Abstract][Full Text] [Related]
16. Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer's disease.
Penny LK; Lofthouse R; Arastoo M; Porter A; Palliyil S; Harrington CR; Wischik CM
Transl Neurodegener; 2024 May; 13(1):25. PubMed ID: 38773569
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
[TBL] [Abstract][Full Text] [Related]
18. Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease.
Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Lozupone M; Santamato A; Zecca C; Barulli MR; Bellomo A; Pilotto A; Daniele A; Greco A; Logroscino G
Biomed Res Int; 2016; 2016():3245935. PubMed ID: 27429978
[TBL] [Abstract][Full Text] [Related]
19. [Development of SPECT Probes for In Vivo Imaging of β-Amyloid and Tau Aggregates in the Alzheimer's Disease Brain].
Watanabe H
Yakugaku Zasshi; 2017; 137(11):1361-1365. PubMed ID: 29093372
[TBL] [Abstract][Full Text] [Related]
20. [Development of Disease-modifying Therapy for Alzheimer's Disease].
Akiyama H
Brain Nerve; 2016 Apr; 68(4):463-72. PubMed ID: 27056864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
